Auro Pharma Gains on USFDA Approval, But Ends Day in the Red

Shares of $AUROPHARMA climbed up to 2.2% on Friday, 5 June 2026, after the company received final approval from the US Food & Drug Administration (USFDA) for Tofacitinib Tablets, 5 mg and 10 mg. The drug is bioequivalent and therapeutically equivalent to Xeljanz Tablets of PF Prism CV and will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of the company. The company announced that the product would be launched immediately, boosting investor sentiment during early trade. However, the optimism faded as the session progressed, with selling pressure eroding all intraday gains. The stock ultimately closed 0.09% lower, despite the positive regulatory development. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes only. Investors must verify information before investing and consider their financial position & risk profile.